# Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

> **NCT06176729** · PHASE2 · RECRUITING · sponsor: **Yan Zhang, MD** · enrollment: 30 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab Vedotin, Rituximab, Lenalidomide

## Key facts

- **NCT ID:** NCT06176729
- **Lead sponsor:** Yan Zhang, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-24
- **Primary completion:** 2025-10-24
- **Final completion:** 2027-10-24
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-12-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06176729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06176729, "Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06176729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*